Regeneron stock: Q3 revenue jumps 36% as Sanofi alliance expands
Published on 11/06/2026 at 15:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGrowth Meets Sanofi Expansion
- Third-quarter revenue reached 5.116 billion US dollars, while non-GAAP diluted earnings per share rose to 20.07 US dollars.
- Regeneron and Sanofi added four next-generation, long-acting antibodies to their alliance with equal cost and profit sharing.
- Management expects an FDA decision on cemdisiran for generalized myasthenia gravis in November 2026.
Regeneron stock traded at 798.20 euros on Lang & Schwarz at 15:00 CET on Friday, November 6, 2026. The company is drawing investor attention after strong third-quarter growth and an expanded antibody alliance with Sanofi.
In its October 30 financial release, Regeneron said third-quarter 2026 revenue rose 36 percent from the year-earlier period to 5.116 billion US dollars. GAAP net income increased 33 percent to 1.949 billion US dollars, while diluted GAAP earnings per share rose 35 percent to 18.45 US dollars.
Sanofi Partnership Broadens
The quarter also marked a step-up in collaboration income. Sanofi collaboration revenue reached 2.724 billion US dollars, compared with 1.617 billion US dollars a year earlier. Regeneron attributed the increase primarily to its larger share of antibody commercialization profits and the full repayment of Sanofi's development balance in the second quarter.
Dupixent global net sales, recorded by Sanofi, rose 35 percent to 6.5 billion US dollars. Regeneron's EYLEA HD US sales increased 62 percent to 699 million US dollars, while global Libtayo sales rose 51 percent to 550 million US dollars. The product mix shows that collaboration income remains the largest near-term earnings driver, while growth in EYLEA HD and Libtayo supports the company's own commercial portfolio.
In October, Regeneron and Sanofi amended their antibody collaboration to add four Regeneron-invented, next-generation, long-acting antibodies. The companies will share development and commercialization costs equally and, if the programs reach the market, split global profits equally. Regeneron received a 1.0 billion US dollar upfront payment and is eligible for up to 7.0 billion US dollars in additional development, regulatory and sales milestones. Management expects to recognize the upfront payment as collaboration revenue in the fourth quarter.
Pipeline Adds Near-Term Catalysts
Chief Executive Leonard Schleifer said the company has a pipeline of about 50 product candidates and highlighted continued progress in immunology, oncology, metabolic disease and rare disease. The company expects an FDA decision on cemdisiran for generalized myasthenia gravis in November 2026. Other disclosed milestones include planned data presentations in MASH and POTS during November and regulatory decisions for additional oncology applications in 2027.
For investors, the expanded Sanofi agreement strengthens Regeneron's longer-term antibody platform but also increases the importance of clinical execution and regulatory delivery. The upfront payment provides a visible fourth-quarter revenue item; future milestone income remains conditional on development, regulatory and commercial achievements.
Investors can follow the real-time quote of Regeneron stock for the latest Lang & Schwarz indication.
U.S. equities remain sensitive to biotechnology earnings, regulatory milestones and healthcare risk appetite; current S&P 500 market reports provide the broader market context.
More news and analyses on Regeneron stock cover further company and pipeline developments.
Regeneron Pharmaceuticals at a Glance
- Company: Regeneron Pharmaceuticals, Inc.
- ISIN: US75886F1075
- Home exchange: Nasdaq
- Lang & Schwarz quote: 798.20 euros, November 6, 2026, 15:00 CET
- Third-quarter revenue: 5.116 billion US dollars, up 36 percent year over year
- Non-GAAP diluted EPS: 20.07 US dollars, up 70 percent year over year
